Insmed Incorporated

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About INSM

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. 

CEO
William H. Lewis
CEOWilliam H. Lewis
Employees
1,271
Employees1,271
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
1988
Founded1988
Employees
1,271
Employees1,271

INSM Key Statistics

Market cap
34.83B
Market cap34.83B
Price-Earnings ratio
-28.98
Price-Earnings ratio-28.98
Dividend yield
Dividend yield
Average volume
1.72M
Average volume1.72M
High today
$167.49
High today$167.49
Low today
$163.82
Low today$163.82
Open price
$166.48
Open price$166.48
Volume
1.53M
Volume1.53M
52 Week high
$168.22
52 Week high$168.22
52 Week low
$60.40
52 Week low$60.40

INSM News

TipRanks 1d
Insmed assumed with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage of Insmed (INSM) with an Overweight rating and $192 price target Following a strong re-rating, Insmed has become a popular lo...

Simply Wall St 2d
How CHMP’s Positive Opinion on BRINSUPRI May Impact Insmed’s Future Growth Prospects

On October 17, 2025, Insmed Incorporated announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive...

How CHMP’s Positive Opinion on BRINSUPRI May Impact Insmed’s Future Growth Prospects
TipRanks 2d
Insmed’s CEDAR Study: A Potential Game-Changer for Hidradenitis Suppurativa Treatment

Insmed ((INSM)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock po...

Analyst ratings

95%

of 20 ratings
Buy
95%
Hold
5%
Sell
0%

More INSM News

TipRanks 6d
Positive Outlook for Insmed: Promising Product Pipeline and Favorable Market Position Justify Buy Rating

Analyst Ashwani Verma from UBS maintained a Buy rating on Insmed and keeping the price target at $194.00. Elevate Your Investing Strategy: Take advantage of Tip...

Simply Wall St 6d
Is Insmed’s 129% Rally in 2025 Justified by the Latest Pipeline Progress?

If you have been watching Insmed stock lately, you are not alone. With the shares coming off a remarkable year-to-date gain of 129.3% and a three-year return th...

Is Insmed’s 129% Rally in 2025 Justified by the Latest Pipeline Progress?

People also own

Based on the portfolios of people who own INSM. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.